

FOR IMMEDIATE RELEASE

ImQuest Pharmaceuticals announces the appointment of Robert Schooley, M.D. to its Scientific Advisory Board.

ImQuest Pharmaceuticals, Inc. announced today the appointment of Robert Schooley, M.D. to its Scientific Advisory Board.

Dr. Robert Schooley is Professor of Medicine and Head of the Division of Infectious Diseases at the University of California, San Diego. He is a graduate of Washington and Lee University and of the Johns Hopkins University School of Medicine. After medical house staff training at the Johns Hopkins Hospital and postdoctoral fellowships in Infectious Diseases at the National Institute of Allergy and Infectious Diseases and the Massachusetts General Hospital, he joined the faculty of Harvard Medical School in 1981. He was recruited from Harvard to the University of Colorado School of Medicine in 1990 where he served as Tim Gill Professor and Head of the Division of Infectious Diseases. He assumed his current position in 2006. Dr. Schooley led the NIAID's AIDS Clinical Trials Group (ACTG) from 1995 to 2002. His research interests include the areas of viral pathogenesis and therapy with a particular emphasis on retroviruses, herpes viruses and hepatitis C virus. Dr. Schooley has contributed to the development of most of the currently available antiretroviral agents for the treatment of HIV infection and has authored over 200 publications.

Commenting on the appointment, ImQuest's CSO, Dr. Robert W. Buckheit, Jr. said, "Dr. Schooley is an expert in the development of anti-HIV drugs and his experience will be invaluable in supporting ImQuest's efforts to progress our highly novel, dual-acting HIV drug candidate (IQP-0410) to the clinic, as well as assisting us to further develop our diversified portfolio of highly active HIV therapeutics and microbicides. We are privileged to welcome Dr. Schooley to our team."

ImQuest Pharmaceuticals, Inc. is a privately held U.S. company located in Frederick, Maryland that specializes in the development of novel, "first-in-class" compounds for the treatment of infectious disease and cancer. Information on ImQuest's therapeutic products and corporate development strategy can be found at www.imquestpharma.com.

For further information regarding this press release please contact:

Robert W. Buckheit, Jr., Ph.D.
Chief Scientific Officer
ImQuest Pharmaceuticals, Inc.
301-696-0274
rbuckheit@imquest.com